tetano
Editor, Senior Moderator
Gastroenterology
. 2022 Apr 28;S0016-5085(22)00450-4.
doi: 10.1053/j.gastro.2022.04.037. Online ahead of print.
Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases
Andreas Zollner[SUP] 1 [/SUP], Robert Koch[SUP] 1 [/SUP], Almina Jukic[SUP] 1 [/SUP], Alexandra Pfister[SUP] 1 [/SUP], Moritz Meyer[SUP] 1 [/SUP], Annika Rössler[SUP] 2 [/SUP], Janine Kimpel[SUP] 2 [/SUP], Timon E Adolph[SUP] 3 [/SUP], Herbert Tilg[SUP] 4 [/SUP]
Affiliations
Abstract
Background and aims: The coronavirus disease 2019 (COVID-19) pandemic affects populations, societies and lives for more than two years. Long-term sequelae of COVID-19, collectively termed the post-acute COVID-19 syndrome, are rapidly emerging across the globe. Here, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen persistence underlies the post-acute COVID-19 syndrome.
Methods: We performed an endoscopy study with 46 inflammatory bowel disease (IBD) patients 219 days (range: 94-257) after a confirmed COVID-19 infection. SARS-CoV-2 antigen persistence was assessed in the small and large intestine by qPCR of four viral transcripts, immunofluorescence of viral nucleocapsid and virus cultivation from biopsy tissue. Post-acute COVID-19 was assessed by a standardized questionnaire, and a systemic SARS-CoV-2 immune response was evaluated by flow-cytometry and ELISA at endoscopy. IBD activity was evaluated by clinical, biochemical and endoscopic means.
Results: We report expression of SARS-CoV-2 RNA in the gut mucosa ∼7 months after mild acute COVID-19 in 32 of 46 patients with IBD. Viral nucleocapsid protein persisted in 24 of 46 patients in gut epithelium and CD8[SUP]+[/SUP] T cells. Expression of SARS-CoV-2 antigens was not detectable in stool and viral antigen persistence was unrelated to severity of acute COVID-19, immunosuppressive therapy and gut inflammation. We were unable to culture SARS-CoV-2 from gut tissue of patients with viral antigen persistence. Post-acute sequelae of COVID-19 were reported from the majority of patients with viral antigen persistence, but not from patients without viral antigen persistence.
Conclusion: Our results indicate that SARS-CoV-2 antigen persistence in infected tissues serves as a basis for post-acute COVID-19. The concept that viral antigen persistence instigates immune perturbation and post-acute COVID-19 requires validation in controlled clinical trials.
Keywords: COVID-19; SARS-CoV-2; post-acute COVID-19; viral antigen persistence.
. 2022 Apr 28;S0016-5085(22)00450-4.
doi: 10.1053/j.gastro.2022.04.037. Online ahead of print.
Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases
Andreas Zollner[SUP] 1 [/SUP], Robert Koch[SUP] 1 [/SUP], Almina Jukic[SUP] 1 [/SUP], Alexandra Pfister[SUP] 1 [/SUP], Moritz Meyer[SUP] 1 [/SUP], Annika Rössler[SUP] 2 [/SUP], Janine Kimpel[SUP] 2 [/SUP], Timon E Adolph[SUP] 3 [/SUP], Herbert Tilg[SUP] 4 [/SUP]
Affiliations
- PMID: 35508284
- DOI: 10.1053/j.gastro.2022.04.037
Abstract
Background and aims: The coronavirus disease 2019 (COVID-19) pandemic affects populations, societies and lives for more than two years. Long-term sequelae of COVID-19, collectively termed the post-acute COVID-19 syndrome, are rapidly emerging across the globe. Here, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen persistence underlies the post-acute COVID-19 syndrome.
Methods: We performed an endoscopy study with 46 inflammatory bowel disease (IBD) patients 219 days (range: 94-257) after a confirmed COVID-19 infection. SARS-CoV-2 antigen persistence was assessed in the small and large intestine by qPCR of four viral transcripts, immunofluorescence of viral nucleocapsid and virus cultivation from biopsy tissue. Post-acute COVID-19 was assessed by a standardized questionnaire, and a systemic SARS-CoV-2 immune response was evaluated by flow-cytometry and ELISA at endoscopy. IBD activity was evaluated by clinical, biochemical and endoscopic means.
Results: We report expression of SARS-CoV-2 RNA in the gut mucosa ∼7 months after mild acute COVID-19 in 32 of 46 patients with IBD. Viral nucleocapsid protein persisted in 24 of 46 patients in gut epithelium and CD8[SUP]+[/SUP] T cells. Expression of SARS-CoV-2 antigens was not detectable in stool and viral antigen persistence was unrelated to severity of acute COVID-19, immunosuppressive therapy and gut inflammation. We were unable to culture SARS-CoV-2 from gut tissue of patients with viral antigen persistence. Post-acute sequelae of COVID-19 were reported from the majority of patients with viral antigen persistence, but not from patients without viral antigen persistence.
Conclusion: Our results indicate that SARS-CoV-2 antigen persistence in infected tissues serves as a basis for post-acute COVID-19. The concept that viral antigen persistence instigates immune perturbation and post-acute COVID-19 requires validation in controlled clinical trials.
Keywords: COVID-19; SARS-CoV-2; post-acute COVID-19; viral antigen persistence.
